BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 8866671)

  • 1. The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain.
    Weller M; Fontana A
    Brain Res Brain Res Rev; 1995 Sep; 21(2):128-51. PubMed ID: 8866671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity against established intracerebral gliomas exhibited by cytotoxic T lymphocytes, but not by lymphokine-activated killer cells.
    Holladay FP; Heitz T; Wood GW
    J Neurosurg; 1992 Nov; 77(5):757-62. PubMed ID: 1403119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines.
    Weller M; Frei K; Groscurth P; Krammer PH; Yonekawa Y; Fontana A
    J Clin Invest; 1994 Sep; 94(3):954-64. PubMed ID: 7521890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploitation of immune mechanisms in the treatment of central nervous system cancer.
    Pollack IF; Okada H; Chambers WH
    Semin Pediatr Neurol; 2000 Jun; 7(2):131-43. PubMed ID: 10914414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular immunotherapy for malignant gliomas.
    Lin Y; Okada H
    Expert Opin Biol Ther; 2016 Oct; 16(10):1265-75. PubMed ID: 27434205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.
    Uhl M; Aulwurm S; Wischhusen J; Weiler M; Ma JY; Almirez R; Mangadu R; Liu YW; Platten M; Herrlinger U; Murphy A; Wong DH; Wick W; Higgins LS; Weller M
    Cancer Res; 2004 Nov; 64(21):7954-61. PubMed ID: 15520202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endogenous expression of transforming growth factor beta1 inhibits growth and tumorigenicity and enhances Fas-mediated apoptosis in a murine high-grade glioma model.
    Ashley DM; Kong FM; Bigner DD; Hale LP
    Cancer Res; 1998 Jan; 58(2):302-9. PubMed ID: 9443409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines.
    Ueda R; Fujita M; Zhu X; Sasaki K; Kastenhuber ER; Kohanbash G; McDonald HA; Harper J; Lonning S; Okada H
    Clin Cancer Res; 2009 Nov; 15(21):6551-9. PubMed ID: 19861464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of transforming growth factor-beta 2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma.
    Jachimczak P; Bogdahn U; Schneider J; Behl C; Meixensberger J; Apfel R; Dörries R; Schlingensiepen KH; Brysch W
    J Neurosurg; 1993 Jun; 78(6):944-51. PubMed ID: 8487077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cellular immunotherapy for malignant glioma].
    Okamoto Y; Yamashita J
    Nihon Rinsho; 2005 Sep; 63 Suppl 9():557-62. PubMed ID: 16201581
    [No Abstract]   [Full Text] [Related]  

  • 11. Decorin gene transfer-mediated suppression of TGF-beta synthesis abrogates experimental malignant glioma growth in vivo.
    Ständer M; Naumann U; Dumitrescu L; Heneka M; Löschmann P; Gulbins E; Dichgans J; Weller M
    Gene Ther; 1998 Sep; 5(9):1187-94. PubMed ID: 9930319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fas/APO-1 gene transfer for human malignant glioma.
    Weller M; Malipiero U; Rensing-Ehl A; Barr PJ; Fontana A
    Cancer Res; 1995 Jul; 55(13):2936-44. PubMed ID: 7540953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune stimulatory effects of CD70 override CD70-mediated immune cell apoptosis in rodent glioma models and confer long-lasting antiglioma immunity in vivo.
    Aulwurm S; Wischhusen J; Friese M; Borst J; Weller M
    Int J Cancer; 2006 Apr; 118(7):1728-35. PubMed ID: 16217761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infiltration of tumor-reactive transforming growth factor-beta insensitive CD8+ T cells into the tumor parenchyma is associated with apoptosis and rejection of tumor cells.
    Zhang Q; Jang TL; Yang X; Park I; Meyer RE; Kundu S; Pins M; Javonovic B; Kuzel T; Kim SJ; Van Parijs L; Smith N; Wong L; Greenberg NM; Guo Y; Lee C
    Prostate; 2006 Feb; 66(3):235-47. PubMed ID: 16173028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-β.
    Lohr J; Ratliff T; Huppertz A; Ge Y; Dictus C; Ahmadi R; Grau S; Hiraoka N; Eckstein V; Ecker RC; Korff T; von Deimling A; Unterberg A; Beckhove P; Herold-Mende C
    Clin Cancer Res; 2011 Jul; 17(13):4296-308. PubMed ID: 21478334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation.
    Weller M; Malipiero U; Aguzzi A; Reed JC; Fontana A
    J Clin Invest; 1995 Jun; 95(6):2633-43. PubMed ID: 7539458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo.
    Friese MA; Wischhusen J; Wick W; Weiler M; Eisele G; Steinle A; Weller M
    Cancer Res; 2004 Oct; 64(20):7596-603. PubMed ID: 15492287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy.
    Zhang L; Yu Z; Muranski P; Palmer DC; Restifo NP; Rosenberg SA; Morgan RA
    Gene Ther; 2013 May; 20(5):575-80. PubMed ID: 22972494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of TGF-beta on the immune system: implications for cancer immunotherapy.
    de Visser KE; Kast WM
    Leukemia; 1999 Aug; 13(8):1188-99. PubMed ID: 10450746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8
    Zhang Q; Helfand BT; Carneiro BA; Qin W; Yang XJ; Lee C; Zhang W; Giles FJ; Cristofanilli M; Kuzel TM
    Eur Urol; 2018 May; 73(5):648-652. PubMed ID: 29275833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.